New Drugs 2020 – Nurse, Nurse Practitioner
Price $10.00
Credits 2
Format
During 2020, the global pandemic pressured the FDA to focus on treatments, diagnostic tests, and prevention measures for SARS-CoV-2, the cause of COVID-19. However, the agency still approved 53 drugs as new molecular entities or new biologics – an increase over the 48 novel drugs approved in 2019. This issue summarizes key information on new, first-in-class medications for cholesterol management and two common skin conditions (acne vulgaris and actinic keratosis); the first drug for peanut allergy; the first oral gonadotropin-releasing hormone antagonist for prostate cancer; a new and improved pediculicide and ovicide for head lice; and a new catechol-O-methyltransferase (COMT) inhibitor for Parkinson’s disease. A brief summary of 4 new oral therapies for non-small cell lung cancer (NSCLC) is also included. Usual dosing recommendations and drug interactions are provided in Table 1.Brief descriptions of 14 additional new drugs that may be commonly prescribed are provided in Table 2.
